Bridgitte Lee
Optometrist · Houston, TXNPI 1114017175
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $140,055 of the $221,952 with a category attached, or 63.1%. 26 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 36.8% of the total. Among optometrist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 754 payments — averaging $294.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$82K
- Bausch & Lomb Americas Inc.$41K
- Lumenis BE Inc$16K
- Dompe US, Inc.$13K
- Johnson & Johnson Vision Care, Inc.$13K
- Alcon$13K
- plus $44K from 20 others
Across 86 payments — averaging $34,934 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tarsus Pharmaceuticals, Inc.$2.9M
- Johnson & Johnson Vision Care, Inc.$116K
- Alcon Research LLC$11K
- Novartis$5K
What the payments were for
- Consulting fees$26,25312%
- Speaking & faculty fees$140,05563%
- Travel & lodging$17,9408%
- Food & beverage$21,29510%
- Education$16,3027%
- Entertainment$1080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 155 | $81,649 |
| Bausch & Lomb Americas Inc. | 121 | $40,763 |
| Lumenis BE Inc | 4 | $16,129 |
| Dompe US, Inc. | 45 | $13,489 |
| Johnson & Johnson Vision Care, Inc. | 98 | $13,337 |
| Alcon | 73 | $13,048 |
| Kala Pharmaceuticals, Inc. | 12 | $8,817 |
| Lumenis, Inc | 7 | $8,055 |
| Coopervision Inc. | 62 | $7,362 |
| Tarsus Pharmaceuticals, Inc. | 34 | $6,376 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $4,992 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 32 | $2,235 |
| Shire North American Group Inc | 12 | $1,204 |
| Biotissue Holdings Inc. | 6 | $1,051 |
| Lumenis Ltd. | 1 | $750 |
| Visioneering Technologies, Inc. | 6 | $518 |
| AbbVie(2 entities) | 19 | $492 |
| Novartis | 20 | $490 |
| Oyster Point Pharma, Inc. | 18 | $419 |
| Carl Zeiss Meditec, Inc. | 1 | $350 |
| Harrow Eye, LLC | 7 | $185 |
| Optos, Inc. | 3 | $108 |
| Eyevance Pharmaceuticals LLC | 2 | $49 |
| Mylan Inc. | 1 | $46 |
| Carl Zeiss Meditec USA, Inc. | 1 | $22 |
| Thea Pharma Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$79,031
- MIEBO$28,918
- XIIDRA$26,539
- optilight$16,129
- Oxervate$12,465
- EYSUVIS$8,680
- Acuvue$8,139
- DAILIES$6,251
- Precision 1$5,500
- Dailies Aqua Comfort Plus$3,500
- AIR OPTIX$3,500
- DAILIES TOTAL1$3,500
- Air Optix plus HydraGlyde$3,000
- MiSight Contact Lens$2,860
- TearScience Lipiflow System$2,700
- TearScience Activators$2,100
- TearScience Lipiscan System$2,100
- TearScience Lipiview System$2,100
- Lumenis Pulse 120H$2,000
- MyDay Contact Lens$1,705
How this compares
$221,952 in reported general payments places this provider in the 95th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 45 | $82,518 |
| MieboPerfluorohexyloctane/Pf | 21 | $15,713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $6,376 | $82,51845 claims |
| Bausch & Lomb Americas Inc.Miebo | $40,763 | $15,71321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Houston
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$547K
- Phillip BrunsonHouston$214K
- Maria WalkerHouston$128K
- Seema NandaHouston$87K
- Danica MarrelliHouston$87K
- Richard BakerHouston$78K
- Karen LeeHouston$71K
- Nishi MehdirattaHouston$45K
- Ali MostaghimiHouston$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.